Bayer Overview
- Year Founded
-
1863
- Status
-
Public
- Employees
-
87,775
- Stock Symbol
-
BAYN
- Investments
-
109
- Share Price
-
$59.99
- (As of Thursday Closing)
Bayer General Information
Description
Bayer is a German healthcare and agriculture conglomerate. Healthcare accounts for close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total sales). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, a segment that was expanded through its 2018 acquisition of Monsanto.
Contact Information
Website
www.bayer.comCorporate Office
- Kaiser-Wilhelm-Allee 1
- 51373 Leverkusen
- Germany
Corporate Office
- Kaiser-Wilhelm-Allee 1
- 51373 Leverkusen
- Germany
Bayer Timeline
Bayer Stock Performance
As of 19-Nov-2026, Bayer’s stock price is $59.99. Its current market cap is $58.9B with 982M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $59.99 | $61.49 | $30.73 - $64.84 | $58.9B | 982M | 2.33M | -$1.71 |
Bayer Financials Summary
As of 30-Sep-2026, Bayer has a trailing 12-month revenue of $53.2B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 91,379,459 | 81,083,151 | 56,244,174 | 78,926,956 |
| Revenue | 53,175,940 | 51,408,880 | 50,432,298 | 51,546,827 |
| EBITDA | 6,269,389 | 3,442,675 | 4,232,089 | 4,600,985 |
| Net Income | (1,681,209) | (4,083,382) | (2,761,516) | (3,182,384) |
| Total Assets | 128,675,920 | 122,795,828 | 115,347,395 | 128,512,684 |
| Total Debt | 49,244,744 | 42,818,380 | 42,348,155 | 47,392,914 |
Bayer Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bayer Comparisons
Industry
Financing
Details
Bayer Competitors (3)
One of Bayer’s 3 competitors is GSK, a Corporation company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GSK | Corporation | London, United Kingdom | ||||
| UPL | Corporation | Mumbai, India | ||||
| Merck | Corporation | Darmstadt, Germany |
Bayer Patents
Bayer Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4837922-A1 | Antibodies and radiopharmaceutical complexes targeting ceacam5 | Pending | 10-May-2025 | ||
| WO-2026233830-A1 | Device for the targeted application of a liquid to an agricultural field | Pending | 09-May-2025 | ||
| WO-2026234145-A1 | Lactam-derivatives as sos1 inhibitors | Pending | 09-May-2025 | ||
| WO-2026236473-A1 | Magnetic resonance contrast media injector system | Pending | 08-May-2025 | ||
| WO-2026236478-A1 | Magnetic resonance contrast media injector system | Pending | 08-May-2025 |
Bayer Signals
Bayer Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Bayer Investments & Acquisitions (109)
Bayer’s most recent deal was a Merger/Acquisition with Perfuse Therapeutics for . The deal was made on 17-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Perfuse Therapeutics | 17-Jun-2026 | Merger/Acquisition | Drug Discovery | ||
| Attralus (Portfolio of 2 Investigational Imaging Agents for Diagnosis of Cardiac Amyloidosis) | 12-Jan-2026 | Corporate Asset Purchase | Buildings and Property | ||
| Ukko | 25-Jun-2025 | Later Stage VC | Drug Discovery | ||
| Aferna | 04-Jun-2025 | Early Stage VC | Other Commercial Products | ||
| Cara Care | 18-Mar-2025 | Merger/Acquisition | Application Software |
Bayer ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
20.24 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Bayer Exits (34)
Bayer’s most recent exit was on 02-Oct-2024 from Guardian Agriculture. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Guardian Agriculture | 02-Oct-2024 | Completed |
|
||
| Mothus | 04-Dec-2023 | Completed |
|
||
| Blackford Analysis | 18-Jan-2023 | Completed |
|
||
| Projini | 01-Jun-2021 | Completed |
|
||
| Senti Biosciences Holdings | 06-Jan-2021 | Later Stage VC | Completed |
|
Bayer Affiliates
Subsidiaries (50)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Bayer World Investments | Hoofddorp, Netherlands | 2022 | |
| Bayer Global Investments | Hoofddorp, Netherlands | 2022 | |
| Natsana | Dusseldorf, Germany | 2019 | |
| Perfuse Therapeutics | South San Francisco, CA | 2018 | |
| KaNDy Therapeutics | Stevenage, United Kingdom | 2017 |
Bayer FAQs
-
When was Bayer founded?
Bayer was founded in 1863.
-
Where is Bayer headquartered?
Bayer is headquartered in Leverkusen, Germany.
-
What is the size of Bayer?
Bayer has 87,775 total employees.
-
What industry is Bayer in?
Bayer’s primary industry is Conglomerates.
-
Is Bayer a private or public company?
Bayer is a Public company.
-
What is Bayer’s stock symbol?
The ticker symbol for Bayer is BAYN.
-
What is the current stock price of Bayer?
As of 19-Nov-2026 the stock price of Bayer is $59.99.
-
What is the current market cap of Bayer?
The current market capitalization of Bayer is $58.9B.
-
What is Bayer’s current revenue?
The trailing twelve month revenue for Bayer is $53.2B.
-
Who are Bayer’s competitors?
-
What is Bayer’s annual earnings per share (EPS)?
Bayer’s EPS for 12 months was -$1.71.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process